Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with concurrent thoracic radiotherapy in unresectable stage III EGFR-mutated NSCLC
jRCTs041180080Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Progression-free survival rate at 2 years. Started Jan 2013; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041180080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180080.